Find Funding Opportunities

-Purpose. This Funding Opportunity Announcement (FOA) issued by the Office of Research on Women's Health (ORWH) and co-sponsoring Institutes and Centers (ICs) of the National Institutes of Health (NIH) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology, and treatment of chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME/CFS) in diverse groups and across the lifespan. Innovative applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among patient populations, and the common mechanisms influencing the multiple body systems that are affected in CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of the disease process and provide evidence based solutions to improve the diagnosis, treatment, and quality of life of all persons with CFS. -Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanismand runs in parallel with a FOA of identical scientific scope, PA-08-246 that encourages applications under the,(R01) mechanism -Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.

-Purpose. This FOA solicits Research Project Grant (R01) applications from institutions/organizations proposing exceptionally innovative research on novel hypotheses or difficult problems, solutions to which would have an extremely high impact on biomedical or biobehavioral research that is germane to the mission of one or more of the participating NIH Institutes. This FOA is for support of new projects, not continuation of projects that have already been initiated. It does not support pilot projects, i.e., projects of limited scope that are designed primarily to generate data that will enable the PI to seek other funding opportunities. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism. -Funds Available and Anticipated Number of Awards. NIGMS ($6 million, 18-22 awards), NCI ($750,000, 2-3 awards), NIA ($1 million, 2-3 awards), NIAAA ($600,000, 2 awards), NIDCR ($750,000, 2-3 awards), NIDA ($1 million, 3-4 awards), NIMH ($3 million, 8-12 awards), NINDS ($2 million, 6 awards), and NLM ($985,000. 3 awards) are participating in this initiative. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

-Purpose. This Funding Opportunity Announcement (FOA) requests applications for projects intended to complete preliminary steps in the pipeline for the pre-clinical development of therapeutics for neurological disorders.Such projects, if successful, should lead directly to a subsequent project that will include all remaining activities for submission of an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application to the Food and Drug Administration (FDA).Only Aims required for therapy development can be supported in this program.This program excludes clinical research, basic research and studies of disease mechanism. -Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism. -Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

-Purpose. The goal of this funding opportunity announcement (FOA) is to support pre-clinical development and testing of new therapies for neurological disorders.The program will facilitate solicitation, development, and review of therapy-directed projects to accelerate the translation of basic research discoveries into therapeutic candidates for clinical testing.This program is specifically directed at projects that include therapeutic leads with demonstrated activity against the intended disease target.The program supports pre-clinical optimization and testing of these leads and projects must be sufficiently advanced that an IND or IDE application to the FDA can be submitted by the end of the project period. The program does not support early-stage therapeutic discovery activities such as high throughput screening.The program also excludes clinical research, basic research, and studies of disease mechanism.This is a milestone-driven cooperative agreement program involving participation of NINDS staff in the development of the project plan and monitoring of research progress. -Mechanism of Support. This FOA will utilize the U01 Research Project Cooperative Agreements grant mechanism.

-Purpose. The goal of this funding opportunity announcement (FOA) is to support pre-clinical development and testing of new therapies for neurological disorders.The program will facilitate solicitation, development, and review of therapy-directed projects to accelerate the translation of basic research discoveries into therapeutic candidates for clinical testing.This program is specifically directed at projects that include therapeutic leads with demonstrated activity against the intended disease target.The program supports pre-clinical optimization and testing of these leads and projects must be sufficiently advanced that an IND or IDE application to the FDA can be submitted by the end of the project period. The program does not support early-stage therapeutic discovery activities such as high throughput screening.The program also excludes clinical research, basic research, and studies of disease mechanism.This is a milestone-driven cooperative agreement program involving participation of NINDS staff in the development of the project plan and monitoring of research progress. -Mechanism of Support. This FOA will utilize the U54 Specialized Center Cooperative Agreements grant mechanism. -Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

-Purpose. This FOA requests applications Phase II and Fast-Track SBIR cooperative agreement projects that directly address the identification and pre-clinical testing of new therapeutics for neurological disorders.The program will facilitate solicitation, development, and review of therapy-directed projects to accelerate the translation of basic research discoveries into therapeutic candidates for clinical testing.This program is specifically directed at projects that include therapeutic leads with demonstrated activity against the intended disease target.The program supports pre-clinical optimization and testing of these leads and projects must be sufficiently advanced that an IND or IDE application to the FDA can be submitted by the end of the project period. The program does not support early-stage therapeutic discovery activities such as high throughput screening.The program also excludes clinical research, basic research, and studies of disease mechanism.This is a milestone-driven cooperative agreement program involving participation of NINDS staff in the development of the project plan and monitoring of research progress. -Mechanism of Support. This FOA will utilize the SBIR Cooperative Agreements (U44) grant mechanism for Phase II and Fast-Track applications. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

-Purpose. The goal of this funding opportunity announcement (FOA) is to implement a program of cooperative agreements that will support milestone-driven resource-related projects focused on providing products and services that are required for the pre-clinical testing of new therapeutics, and that are specific to neurology. -Mechanism of Support. This FOA will utilize the U24 Resource-Related Research Projects Cooperative Agreements grant mechanism. -Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

-Purpose. This Funding Opportunity Announcement (FOA), from the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), requests applications for projects intended to complete preliminary steps in the pipeline for the preclinical development of therapeutics for neuromuscular diseases. Such projects, if successful, should lead directly to a subsequent project that will include all remaining activities for submission of an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application to the Food and Drug Administration (FDA). Only Aims required for therapy development can be supported in this program.This program excludes clinical research, basic research, and studies of disease mechanisms. -Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism. -Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.The participating organizations intend to commit a total of $1 million per year to fund meritorious applications that address the goals of this FOA.

-Purpose. The goal of this funding opportunity announcement (FOA), from the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), is to support preclinical development and testing of new therapies for neuromuscular diseases. The program will facilitate solicitation, development, and review of therapy-directed projects to accelerate the translation of basic research discoveries into therapeutic candidates for clinical testing. This program is specifically directed at projects that include therapeutic leads with demonstrated activity against the intended disease target. The program supports preclinical optimization and testing of these leads and projects must be sufficiently advanced that an IND or IDE application to the FDA can be submitted by the end of the project period. The program does not support early-stage therapeutic discovery activities such as high throughput screening. The program also excludes clinical research, basic research, and studies of disease mechanism. This is a milestone-driven cooperative agreement program involving participation of NIH staff in the development of the project plan and monitoring of research progress.

-Purpose: The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible institutions as the primary means of supporting predoctoral and postdoctoral research training to help ensure that a diverse and highly trained workforce is available to assume leadership roles related to the Nations biomedical, behavioral and clinical research agenda.The primary objective of the T32 program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program supports predoctoral, postdoctoral and short term research training programs at domestic institutions of higher education with the T32 funding mechanism. Note that programs solely for short-term research training should not apply to this announcement, but rather the separate (T35) NRSA Short-Term Institutional program exclusively reserved for short-term programs(see PA-08-227). -Mechanism of Support:This Funding Opportunity Announcement (FOA) will utilize the Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32). -Funds Available and Anticipated Number of Awards: Because the nature and scope of the proposed research training will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the number, quality, duration, and costs of the applications received